Eko Health

What Eko Health does

Eko Health, founded in 2013 and headquartered in Emeryville, California, is a digital health company that builds AI-augmented digital stethoscopes and associated software for cardiac and pulmonary disease detection. The company's hardware portfolio includes the flagship CORE 500 Digital Stethoscope (40x sound amplification, active noise cancellation, 3-lead ECG, Bluetooth connectivity), the CORE Digital Attachment (which converts existing acoustic stethoscopes into digital/AI-enabled devices and is integrated into the 3M Littmann CORE), and the DUO ECG + Digital Stethoscope. On top of this hardware, Eko runs a proprietary AI software stack that analyzes phonocardiogram and ECG signals in under one minute to detect heart murmurs, low ejection fraction (a heart failure marker), and atrial fibrillation, with nine FDA 510(k) clearances covering its analysis software, devices, and AI modules including EMAS (murmur classification), ELEFT (low ejection fraction), and EFAST (transformer-based foundation analysis). The platform is supported by the Eko Dashboard and mobile apps on iOS, Android, and Windows, and integrates with electronic health record systems.

Eko generates revenue through a multi-stream model: (1) one-time hardware sales via its e-commerce storefront (ekohealth.com/shop), a global reseller/dealer network, and an OEM partnership with 3M (Littmann CORE Digital Stethoscope); (2) the Eko+ subscription membership granting access to AI analysis in approved jurisdictions on a monthly or annual auto-renewing basis; (3) enterprise software licenses for the SENSORA platform and Eko Telehealth sold to hospital networks; and (4) professional services through its Life Science business for clinical trial cardiac monitoring. The company has sold over 750,000 devices globally, with telehealth deployed across 800+ U.S. hospitals. Recent regulatory milestones — a Category III CPT code effective July 2025 and CMS OPPS payment finalization in December 2025 — enable health systems to bill approximately USD 120 per AI-assisted cardiac exam, creating a utilization-linked revenue pathway. Geographic reach spans the U.S., U.K., Canada, Europe, Singapore, and Sub-Saharan Africa (where the DAMSUN-HF heart failure study was conducted in Ghana).

Eko serves multiple customer segments: individual clinicians and smaller practices (via direct e-commerce and team orders); health systems and hospital networks (via enterprise sales of SENSORA, telehealth, and EHR integrations, with named deployments at Sutter Health, Wayne General Hospital, and Origin Healthcare); life sciences companies (for clinical trial cardiac screening and patient safety monitoring); and veterinary practices (via the Eko Vet+ product with CANINEBEAT AI distributed by Boehringer Ingelheim). Operational certifications include FDA clearances, CE/UKCA marking, Health Canada approval, MDSAP, ISO 13485:2016, and SOC 2 Type II. Recent strategic moves include the April 2025 U.K. and Canada launches, the April 2026 Boehringer Ingelheim veterinary partnership, and the May 2026 appointment of Dr. Steven Steinhubl as Chief Medical Officer.

Name

Eko Health

Legal name

Eko Health, Inc.

Website

https://ekohealth.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

101–250 employees

Short description

Eko Health builds FDA-cleared AI-powered digital stethoscopes and the SENSORA cardiac detection platform, serving clinicians, health systems, telehealth providers, life sciences, and veterinary practices across 800+ U.S. hospitals and 750,000+ devices sold globally.

Ownership category

akta.pro rank

Product category

Medical Diagnostic Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB)

akta.pro secondary industries

Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI), Cardiology Telemedicine Platforms (HLALAGAB), Chronic Disease Management IoT (Diabetes, CHF, COPD, Hypertension) (HLACAPAD)

Keywords

• Digital stethoscopes
• AI cardiac detection
• Cardiac screening software
• Telehealth platforms
• Medical AI diagnostics

Headquarters

HQ city

Emeryville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Hardware Device Sales: Eko sells digital stethoscope hardware (CORE 500, CORE Digital Attachment, DUO ECG + Digital Stethoscope) as one-time purchases through its e-commerce storefront, dealer network, and enterprise sales. List price promotions (e.g., $75 off select colors) are used. This is the primary land product.
2. Eko+ Subscription Membership: Monthly or annual subscription (auto-renewing) that provides access to Eko AI analysis software in regions with regulatory approval. Marketed as Eko+ membership hub. Additional subscription tiers exist for Eko Vet+ (veterinary). Both monthly and annual billing cadences are offered.
3. Enterprise Software Licenses (SENSORA, Telehealth): Health systems pay for SENSORA platform deployment and telehealth integration, typically as multi-year enterprise agreements. The platform has CPT reimbursement codes (Category III CPT code effective July 2025, CMS OPPS payment finalized) enabling health system billing for AI-enabled cardiac exams, creating a value-based revenue cycle.
4. Professional Services & Training: Eko provides clinical education, onboarding, and implementation support to health system customers. The Eko Academy app and CME eligibility provide ongoing education services. Life Science solutions (clinical trial screening and monitoring) represent a B2B professional services stream.

Pricing tiers

Go-to-market motion4 records

Distribution channels7 records

Marketing channels7 records

Core offering

Eko Health develops and sells AI-powered digital stethoscopes (CORE 500, CORE Digital Attachment, DUO ECG + Digital Stethoscope, and 3M Littmann CORE Digital Stethoscope) paired with FDA-cleared AI software (SENSORA platform, EMAS, ELEFT, EFAST) that detect heart murmurs, atrial fibrillation, and low ejection fraction in under one minute. The company also operates an Eko Telehealth platform for virtual cardiac and pulmonary exams and offers Eko Vet+ with CANINEBEAT AI for canine heart murmur detection, distributing through direct e-commerce, enterprise health system sales, 3M OEM, and global resellers.

Product overview

Eko Health offers a platform-plus-modules architecture combining hardware devices, AI-powered software, and cloud services for cardiac and pulmonary disease detection. The core product portfolio includes the CORE 500 Digital Stethoscope (flagship advanced device with 3-lead ECG and AI), the CORE Digital Attachment (converts existing stethoscopes to smart devices), the DUO ECG + Digital Stethoscope (handheld ECG plus acoustic capability), and the 3M Littmann CORE Digital Stethoscope (partnership product). These devices feed into the SENSORA Platform—an FDA-cleared AI analysis system that processes heart sounds to detect murmurs, AFib, and low ejection fraction in under one minute. The Eko Telehealth platform enables remote cardiac assessments across health systems. Software modules include EMAS (murmur classification), ELEFT (low ejection fraction detection), and EFAST (transformer-based analysis). The Eko+ subscription provides cloud AI access, while Eko Vet+ extends the technology to veterinary care for canine heart murmur detection.

Differentiator

Problem solved

Functional benefit

Brands

• SENSORA: FDA-cleared AI-assisted cardiac detection platform that analyzes high-fidelity heart sounds to identify structural heart disease, low ejection fraction, and atrial fibrillation.
• Eko Telehealth
• Eko Vet+
• Eko+ Membership
• CORE 500
• CORE Digital Attachment
• DUO

Products and services

• CORE 500 Digital Stethoscope Flagship advanced digital stethoscope featuring 40x sound amplification, active noise cancellation, up to 8 digital audio filters (heart, pulmonary, wide), 3-lead ECG, Bluetooth connectivity, real-time waveform visualization, and FDA-cleared AI analysis for detecting murmurs, AFib, and low ejection fraction in under one minute. Sold to individual clinicians and health systems.
• CORE Digital Attachment Digital attachment that converts traditional stethoscopes into smart diagnostic tools with amplified audio, recording capabilities, Bluetooth streaming, and AI analysis. Compatible with the 3M Littmann CORE Digital Stethoscope and other stethoscope models. Also used as the hardware base for the Eko Vet+ with CANINEBEAT AI veterinary solution.
• DUO ECG + Digital Stethoscope Handheld device combining 1-lead ECG and digital stethoscope functionality, enabling clinicians to capture both heart electrical signals and acoustic heart sounds for comprehensive cardiac assessment including AFib, tachycardia, bradycardia, and irregular rhythm detection.
• 3M Littmann CORE Digital Stethoscope OEM partnership product combining 3M Littmann's traditional stethoscope design with Eko's digital attachment technology, AI capabilities, and Bluetooth connectivity for enhanced cardiac diagnostics. Sold through 3M's global distribution channels.
• SENSORA Platform FDA-cleared AI-assisted cardiac detection platform that analyzes high-fidelity heart sounds captured by Eko digital stethoscopes in under one minute to detect structural heart disease, low ejection fraction, and atrial fibrillation at the point of care. Deployed across health systems operating 800+ U.S. hospitals, with CE and UKCA marking for international markets. Multi-year enterprise agreements are quote-based, with CMS reimbursement averaging approximately $120 per AI-assisted cardiac exam.
• Eko Telehealth Platform Cloud-based telehealth platform enabling health systems to conduct AI-assisted virtual cardiac and pulmonary examinations remotely. Supports real-time streaming of stethoscope audio and ECG data during live telehealth consultations, EHR integration, and remote cardiac and pulmonary assessments across hospital and home-based settings.
• Eko+ Membership Subscription membership providing access to Eko AI analysis capabilities, cloud storage for patient recordings, and premium features for licensed healthcare professionals. Available in monthly and annual auto-renewing subscription options with a free trial, and accessible only in countries with applicable regulatory approval.
• Eko Vet+ with CANINEBEAT AI Veterinary-specific digital auscultation solution developed with Boehringer Ingelheim that combines the Eko CORE Digital Attachment with CANINEBEAT AI to detect, visualize, and grade heart murmurs in dogs. Validated on over 4,000 annotated canine heart recordings with greater than 95% sensitivity and specificity, targeting myxomatous mitral valve disease affecting approximately 10% of all dogs.

Quantifiable outcome

• Providers who use Eko are 2x more likely to detect heart disease (vs. unaided auscultation)
• +4 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature8 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Boehringer IngelheimcoreChannel Partner/ Reseller/ Distributor · 30 April 2026Boehringer Ingelheim and Eko Health launched Eko Vet+ with CANINEBEAT AI, a digital auscultation solution for veterinary use detecting heart murmurs in dogs with >95% sensitivity/specificity. The system combines the Eko CORE Digital Attachment with an AI algorithm validated on 4,000+ canine heart recordings. Boehringer Ingelheim leads global commercial distribution, with rollout in the U.S. and U.K. starting April 2026, Germany next, followed by phased global expansion. Targets myxomatous mitral valve disease affecting ~10% of all dogs.
• Wayne General HospitalcoreStrategic or Co-development Partner · 26 February 2026Wayne General Hospital (the only hospital serving Wayne County, Mississippi, and participant in the federal Rural Community Hospital Demonstration program) partnered with Eko to deploy SENSORA AI-assisted cardiac detection across its emergency and primary care departments. The deployment enables AI-powered analysis of heart sounds in under one minute, addressing significantly higher cardiovascular disease rates in rural communities where residents are ~40% more likely to develop heart disease compared to urban populations.
• ImpilominorChannel Partner/ Reseller/ Distributor · 25 November 2025Impilo, a digital health platform operator (The Digital Health Store), announced a strategic partnership with Eko Health to feature the Eko CORE 500 Digital Stethoscope on its platform. The partnership aims to enhance diagnostic capabilities for clinicians through advanced AI-powered health technology and expand Impilo's healthcare delivery ecosystem with innovative diagnostic tools.
• 800+ U.S. Hospital Health Systems (Eko Telehealth)coreStrategic or Co-development Partner · 15 July 2025Eko Health's telehealth platform powers virtual cardiac and pulmonary exams across health systems operating over 800 U.S. hospitals as of July 2025. These enterprise partnerships enable health systems to deliver AI-assisted cardiac detection remotely, integrating with existing clinical workflows and EHR systems.

Scale indicators8 records

Recent moves9 records

Expansion highlights7 records

Direct peers

• AliveCor: AliveCor (KardiaMobile/KardiaStation) sells FDA-cleared consumer and clinical ECG devices with AI arrhythmia detection — directly competing with Eko's DUO ECG + Digital Stethoscope and SENSORA rhythm analysis for point-of-care cardiac screening. Both target primary-care clinicians and operate subscription-style AI software models.
• iRhythm Technologies: iRhythm's Zio long-term cardiac monitoring patch and its deep-learning ECG analytics compete for the same cardiologist and health-system budgets Eko targets with SENSORA and Eko Telehealth. Both companies sell AI-driven cardiac arrhythmia and rhythm analytics into U.S. hospital systems on a recurring revenue basis.

Emerging players

• HeartFlow: HeartFlow applies AI to cardiac imaging (FFR-CT) for coronary disease diagnosis, overlapping with Eko's mission of AI-enabled early cardiac disease detection at the point of care. Both pursue CPT reimbursement pathways and sell enterprise software into cardiology and primary-care channels.
• Butterfly Network: Butterfly Network's handheld, AI-guided ultrasound (iQ3) targets point-of-care cardiac and pulmonary assessment — overlapping with Eko's mission of democratizing cardiac diagnostics and competing for the same primary-care and rural-health budgets and AI-software dollars.
• Tempus AI: Tempus AI provides AI-enabled precision medicine across cardiology and other specialties, with ECG and cardiac-data partnerships. It competes with Eko for enterprise health-system AI budgets and shares the same value proposition of integrating AI cardiac insights into clinical workflows.
• Biofourmis: Biofourmis delivers AI-driven remote patient monitoring and virtual care platforms for cardiovascular and other chronic conditions, overlapping with Eko's Telehealth and chronic-disease use cases. Both sell enterprise software to health systems and pursue reimbursement-enabled care models.

Broad incumbents

• Philips (Cardiac Monitoring): Philips' IntelliVue patient monitoring and biosensor portfolio competes in hospital cardiac telemetry and telehealth, and the company is investing in AI cardiac analytics. As a broad incumbent with global hospital salesforce and EHR integrations, Philips can bundle competing AI functionality into existing capital contracts.
• GE HealthCare: GE HealthCare's patient monitoring, ECG, and AI-enabled cardiology solutions (including Caption Health AI-echocardiography guidance) overlap with Eko's enterprise hospital footprint. As a diversified incumbent, GE offers bundled capital + software contracts that could pressure Eko's stand-alone enterprise SaaS sales motion.
• Welch Allyn / Baxter (Hillrom): Welch Allyn (now part of Baxter via Hillrom) supplies diagnostic instruments and connected vital-sign devices widely used in primary care — directly adjacent to Eko's digital stethoscope and primary-care cardiac screening value proposition, with broader portfolio reach across the clinician office.
• 3M Littmann (Stethoscope business): 3M's Littmann line is the global stethoscope category leader and Eko's OEM partner on the Littmann CORE Digital Stethoscope. While currently a partner, 3M has the brand, distribution, and capability to compete head-on if it chose to internalize AI cardiac detection rather than license Eko's technology.

Market position

Strengths5 records

Weaknesses2 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/eko
• Instagraminstagram.com/ekohealth
• YouTubeyoutube.com/channel/UCd5qLqLhJLq-feJL5cGvnwg
• LinkedInlinkedin.com/company/eko-health
• Xx.com/Eko_Health

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds13 records

Investors32 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eko Health